 Aaron Knox
Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Keratin-5 | 1 | 2014 | 49 | 0.450 |
Why?
| | Receptors, Progesterone | 1 | 2014 | 341 | 0.390 |
Why?
| | Receptors, Estrogen | 1 | 2014 | 424 | 0.370 |
Why?
| | Pituitary Neoplasms | 5 | 2015 | 183 | 0.340 |
Why?
| | Glioma | 2 | 2025 | 353 | 0.320 |
Why?
| | Phosphoribosylglycinamide Formyltransferase | 1 | 2008 | 1 | 0.310 |
Why?
| | Purines | 1 | 2008 | 168 | 0.280 |
Why?
| | Models, Biological | 1 | 2014 | 1689 | 0.270 |
Why?
| | Gonadotrophs | 4 | 2015 | 21 | 0.240 |
Why?
| | Protein-Arginine N-Methyltransferases | 1 | 2025 | 28 | 0.230 |
Why?
| | Brain Neoplasms | 2 | 2025 | 1163 | 0.230 |
Why?
| | Breast Neoplasms | 1 | 2014 | 2131 | 0.190 |
Why?
| | raf Kinases | 1 | 2021 | 11 | 0.190 |
Why?
| | Neoplastic Stem Cells | 1 | 2025 | 377 | 0.180 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 198 | 0.170 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 304 | 0.160 |
Why?
| | Pituitary Gland | 3 | 2015 | 148 | 0.150 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2025 | 1343 | 0.150 |
Why?
| | Adenoma | 2 | 2011 | 212 | 0.150 |
Why?
| | Mutation | 1 | 2008 | 3682 | 0.140 |
Why?
| | Cell Proliferation | 5 | 2025 | 2337 | 0.130 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3168 | 0.120 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 37 | 0.120 |
Why?
| | MCF-7 Cells | 1 | 2014 | 115 | 0.110 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2014 | 133 | 0.110 |
Why?
| | Heterografts | 1 | 2014 | 128 | 0.110 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2014 | 195 | 0.110 |
Why?
| | Small Molecule Libraries | 1 | 2014 | 86 | 0.110 |
Why?
| | Immunophenotyping | 1 | 2014 | 309 | 0.100 |
Why?
| | Prolactinoma | 1 | 2011 | 12 | 0.090 |
Why?
| | Antigens, Differentiation | 1 | 2011 | 82 | 0.090 |
Why?
| | Ki-67 Antigen | 1 | 2011 | 107 | 0.090 |
Why?
| | ErbB Receptors | 1 | 2014 | 601 | 0.090 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2015 | 755 | 0.090 |
Why?
| | Gene Expression Profiling | 2 | 2014 | 1681 | 0.080 |
Why?
| | Glycoproteins | 1 | 2012 | 337 | 0.080 |
Why?
| | Endothelial Cells | 1 | 2014 | 700 | 0.080 |
Why?
| | Mice | 6 | 2025 | 16574 | 0.080 |
Why?
| | Animals | 8 | 2025 | 34487 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2011 | 313 | 0.080 |
Why?
| | Blotting, Northern | 1 | 2008 | 198 | 0.080 |
Why?
| | Cricetulus | 1 | 2008 | 105 | 0.080 |
Why?
| | CHO Cells | 1 | 2008 | 151 | 0.080 |
Why?
| | Biocatalysis | 1 | 2008 | 66 | 0.080 |
Why?
| | Cricetinae | 1 | 2008 | 276 | 0.070 |
Why?
| | Cell Cycle Proteins | 1 | 2012 | 578 | 0.070 |
Why?
| | DNA, Complementary | 1 | 2008 | 266 | 0.070 |
Why?
| | Gene Dosage | 1 | 2008 | 142 | 0.070 |
Why?
| | Cloning, Molecular | 1 | 2008 | 522 | 0.070 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2008 | 281 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2011 | 504 | 0.070 |
Why?
| | DNA-Binding Proteins | 1 | 2014 | 1421 | 0.070 |
Why?
| | Genome | 1 | 2008 | 277 | 0.060 |
Why?
| | Transfection | 1 | 2008 | 891 | 0.060 |
Why?
| | Blotting, Western | 1 | 2008 | 1169 | 0.060 |
Why?
| | Up-Regulation | 3 | 2015 | 822 | 0.060 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2008 | 431 | 0.060 |
Why?
| | Cystathionine beta-Synthase | 1 | 2006 | 68 | 0.060 |
Why?
| | Sequence Analysis, DNA | 1 | 2008 | 771 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2011 | 2669 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2014 | 940 | 0.060 |
Why?
| | Cell Survival | 3 | 2015 | 1073 | 0.060 |
Why?
| | Disease Models, Animal | 1 | 2014 | 3936 | 0.060 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 2820 | 0.050 |
Why?
| | Carcinogenesis | 1 | 2025 | 209 | 0.050 |
Why?
| | Biomarkers | 1 | 2014 | 3874 | 0.050 |
Why?
| | Mice, Transgenic | 1 | 2006 | 2066 | 0.040 |
Why?
| | Down Syndrome | 1 | 2006 | 469 | 0.040 |
Why?
| | Humans | 10 | 2025 | 128020 | 0.040 |
Why?
| | Female | 5 | 2025 | 68017 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2014 | 1663 | 0.040 |
Why?
| | Cell Line | 2 | 2012 | 2736 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2015 | 32 | 0.030 |
Why?
| | Cytoprotection | 1 | 2015 | 50 | 0.030 |
Why?
| | Mutant Proteins | 1 | 2015 | 99 | 0.030 |
Why?
| | E-Selectin | 1 | 2014 | 53 | 0.030 |
Why?
| | Gene Amplification | 1 | 2015 | 103 | 0.030 |
Why?
| | Golgi Apparatus | 1 | 2014 | 98 | 0.030 |
Why?
| | Immunoblotting | 1 | 2014 | 301 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 169 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 268 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2015 | 228 | 0.030 |
Why?
| | Child | 2 | 2025 | 20636 | 0.030 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 257 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2014 | 444 | 0.030 |
Why?
| | Microscopy, Fluorescence | 1 | 2014 | 399 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 419 | 0.030 |
Why?
| | RNA Interference | 1 | 2014 | 441 | 0.030 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 835 | 0.020 |
Why?
| | G2 Phase | 1 | 2012 | 36 | 0.020 |
Why?
| | Genes, Tumor Suppressor | 1 | 2012 | 86 | 0.020 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2012 | 112 | 0.020 |
Why?
| | CpG Islands | 1 | 2012 | 151 | 0.020 |
Why?
| | Reactive Oxygen Species | 1 | 2014 | 582 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2015 | 411 | 0.020 |
Why?
| | Mitotic Index | 1 | 2011 | 26 | 0.020 |
Why?
| | Cavernous Sinus | 1 | 2011 | 17 | 0.020 |
Why?
| | Cytoplasm | 1 | 2012 | 257 | 0.020 |
Why?
| | Genes, p53 | 1 | 2011 | 70 | 0.020 |
Why?
| | Skull Base | 1 | 2011 | 43 | 0.020 |
Why?
| | NF-kappa B | 1 | 2014 | 649 | 0.020 |
Why?
| | Cell Division | 1 | 2012 | 777 | 0.020 |
Why?
| | Tumor Burden | 1 | 2011 | 283 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2011 | 477 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1185 | 0.020 |
Why?
| | Gene Expression | 1 | 2014 | 1454 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1020 | 0.020 |
Why?
| | Gonadotropins, Pituitary | 1 | 2008 | 22 | 0.020 |
Why?
| | DNA Damage | 1 | 2011 | 363 | 0.020 |
Why?
| | Radiography | 1 | 2011 | 794 | 0.020 |
Why?
| | Male | 4 | 2021 | 62758 | 0.020 |
Why?
| | Signal Transduction | 2 | 2015 | 4812 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1198 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2008 | 371 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2008 | 930 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2014 | 4006 | 0.020 |
Why?
| | Diploidy | 1 | 2006 | 13 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2008 | 391 | 0.020 |
Why?
| | Apoptosis | 1 | 2015 | 2425 | 0.020 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2006 | 42 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2011 | 955 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2006 | 313 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 5268 | 0.010 |
Why?
| | Inflammation | 1 | 2014 | 2646 | 0.010 |
Why?
| | Adolescent | 1 | 2021 | 20158 | 0.010 |
Why?
| | Aged | 2 | 2011 | 21892 | 0.010 |
Why?
| | Cognition Disorders | 1 | 2006 | 497 | 0.010 |
Why?
| | Time Factors | 1 | 2011 | 6479 | 0.010 |
Why?
| | Middle Aged | 2 | 2011 | 30813 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2011 | 7029 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3371 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1392 | 0.010 |
Why?
| | Adult | 2 | 2011 | 35177 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2011 | 10110 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2011 | 14404 | 0.010 |
Why?
|
|
Knox's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|